Sanjana et al. developed a CRISPR screen using ∼18,000 single guide RNAs targeting >700 kilobases surrounding the genes NF1, NF2, and CUL3, which were previously reported as involved in BRAF inhibitor resistance in melanoma. This evidence concerns the gene NF1 and melanoma.